{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.7","upperLimit":"13.2","value":"10.7"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"8.9","value":"5.3"},{"groupId":"OG002","lowerLimit":"1.9","upperLimit":"8.3","value":"3.7"},{"comment":"The upper confidence interval was not assessable due to insufficient number of participants with events.","groupId":"OG003","lowerLimit":"2.1","upperLimit":"NA","value":"9.4"},{"groupId":"OG004","lowerLimit":"5.1","upperLimit":"25.3","value":"11.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"25"}],"units":"Participants"}],"description":"A secondary efficacy endpoint is Radiologic Progression-free Survival (rPFS) assessed by IRR. rPFS is defined as the time from first dose of rucaparib to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first, plus 1 day. Radiographic disease progression includes confirmed bone disease progression and soft tissue disease progression adjudicated by IRR using the PCWG3 guidelines for bone disease and modified RECIST Version 1.1 for soft tissue disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor.","id":"OG000","title":"BRCA Mutation"},{"description":"Patients with a deleterious ATM (ataxia telangiectasia mutated serine/threonine kinase) mutation detected in their tumor.","id":"OG001","title":"ATM Mutation"},{"description":"Patients with a deleterious CDK12 (Cyclin-dependent kinase 12) mutation detected in their tumor.","id":"OG002","title":"CDK12 Mutation"},{"description":"Patients with a deleterious CHEK2 (Checkpoint Kinase 2) mutation detected in their tumor.","id":"OG003","title":"CHEK2 Mutation"},{"description":"Patients with other deleterious HRR (homologous recombination repair) gene mutation detected in their tumor.","id":"OG004","title":"Other Gene Mutation"}],"paramType":"MEDIAN","populationDescription":"All patients","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.","title":"Radiologic Progression-free Survival (rPFS) by Gene in All Patients Per Central Independent Radiology Review (IRR)","type":"SECONDARY","unitOfMeasure":"months"}